Vasculitis Screen ELISA Kit

t(8;21)(q22;q22) acute myelogenous leukemia (AML) is morpho-logically characterized by a continuum of heterogeneous leukemia cells from myeloblasts to differentiated myeloid elements. Thus, t(8;21) AML is an excellent model for studying heterogeneous cell populations and cellular evolution during disease progression. Using integrative analyses of immunophenotype, RNA-sequencing (RNA-seq), and single-cell RNA-sequencing (scRNA-seq), we identi-fied three distinct intrapatient leukemic cell populations that were arrested at different stages of myeloid differentiation: CD34*CD117dim blasts, CD34*CD117bri blasts, and abnormal myeloid cells with partial maturation (AM). CD117 is also known as c-KIT protein. CD34*CD117dim cells were blocked in the G0/G1 phase at disease onset, presenting with the regular morphology of myeloblasts showing features of granulocyte-monocyte progenitors (GMP), and were drug-resistant to chemotherapy. Genes associated with cell migration and adhe-sion (LGALS1, EMP3, and ANXA2) were highly expressed in the CD34*CD117dim population. CD34*CD117bri blasts were blocked a bit later than the CD34*CD117dim population in the hematopoietic differentiation stage and displayed high proliferation ability. AM cells, which bear abnormal myelocyte morphology, especially over -expressed granule genes AZU1, ELANE, and PRTN3 and were sensi-tive to chemotherapy. scRNA-seq at different time points identified CD34*CD117dim blasts as an important leukemic cluster that ex-panded at postrelapse refractory stage after several cycles of che-motherapy. Patients with t(8;21) AML with a higher proportion of CD34*CD117dim cells had significantly worse clinical outcomes than those with a lower CD34*CD117dim proportion. Univariate and mul-tivariate analyses identified CD34*CD117dim proportion as an inde-pendent factor for poor disease outcome. Our study provides evidence for the multidimensional heterogeneity of t(8;21)AML and may offer new tools for future disease stratification.

This molecular epidemiology study integrated questionnaire and genotype information to examine a disease susceptibility hypothesis. The study was based on a previously reported association demonstrated between a single nucleotide polymorphism (SNP) identified as A-564G within the promoter of the proteinase-3 gene (PRTN3) and the autoimmune disease Wegener's granulomatosis (WG). To further examine the strength of this association, we employed a family-based design in which the inheritance of alternate alleles could be ascertained from the parents of affected and unaffected progeny. Genotype information for the study participants was derived from DNA samples from participants who collected buccal cells using a harvesting method that was non-invasive and self-administered. A brief questionnaire captured demographic data on the participants, the family relationships between participants, and the prevalence of autoimmune disease among family members. Samples were obtained on 132 individuals representing 43 WG cases and 89 unaffected controls. Thirty-four nuclear families containing at least one unaffected sibling or parent of a WG case were represented in this sample. We found no evidence for an association between A-564G and the likelihood of a WG diagnosis. We examined five additional SNPs and a sixth SNP haplotype within the PRTN3 promoter region in a family-based association analysis and found no evidence that mutations within PRTN3 are associated with WG diagnosis.